Fate Therapeutics (NASDAQ:FATE) just reported results for the first quarter of 2024.
- Fate Therapeutics reported earnings per share of -47 cents. This was above the analyst estimate for EPS of -49 cents.
- The company reported revenue of $1.93 million.
- This was 73.42% better than the analyst estimate for revenue of $1.11 million.